While our in vivo experiments confirmed the potential impact of CXCR4 inhibitor and IL-2 treatments on modulating immune cell dynamics and restricting tumor progression, the precise molecular mechanisms orchestrating these changes require further investigation. This evidence concerns the gene IL2 and neoplasm.